ki:elements

Speech Biomarkers for Dysarthria in Parkinson’s Disease — Clinical Validation Across Spanish and Czech Languages

Baykara, E., Dörr, F., Rusz, J., Orozco-Arroyave, J.R., and Tröger, J. (2024). Speech Biomarkers for Dysarthria in Parkinson’s Disease — Clinical Validation Across Spanish and Czech Languages. Parkinsonism & Related Disorders, 122: 106726. https://doi.org/10.1016/j.parkreldis.2024.106726

Abstract

This study investigates reliable speech biomarkers for Parkinson’s disease-related dysarthria, ensuring cross-language clinical validity. It assesses performance on sustained phonation (SPA) and rapid syllable repetition (DDK), chosen for practicality and reduced patient-burden. ki:elements SIGMA pipeline extracts clinically relevant speech features, controlling for age and gender influences. Composite scores are evaluated for clinical validity using UPDRS-III, UPDRS-Speech, H&Y scales, and assessed across both languages.

FULL ABSTRACT

Share this article